Multiple Sclerosis Drugs - Malaysia

Malaysia

In Malaysia, the Multiple Sclerosis Drugs market is anticipated to achieve a revenue of US$28.67m in 2024.
This indicates an expected annual growth rate (CAGR 2024-2029) of 1.71%, leading to a market volume of US$31.20m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$11,770.00m in 2024.
Malaysia's demand for Multiple Sclerosis Drugs is steadily increasing, driven by a growing awareness and diagnosis of the disease.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Malaysia has been steadily growing in recent years.

Customer preferences: Patients with Multiple Sclerosis in Malaysia prefer drugs that are affordable, effective, and have minimal side effects. They also prefer drugs that are easily accessible and can be obtained without much hassle.

Trends in the market: The Multiple Sclerosis Drugs market in Malaysia has been driven by the increasing prevalence of the disease in the country. The rising awareness about the disease and the availability of effective treatment options have also contributed to the growth of the market. Additionally, the government's efforts to improve healthcare infrastructure and increase healthcare spending have also played a significant role in the growth of the market.

Local special circumstances: Malaysia has a diverse population with varying healthcare needs. The country's healthcare system is also fragmented, with both private and public healthcare providers. This has led to differences in the availability and accessibility of Multiple Sclerosis drugs across different regions of the country.

Underlying macroeconomic factors: The Malaysian economy has been growing steadily in recent years, which has led to an increase in disposable income and healthcare spending. The government's efforts to improve healthcare infrastructure and increase healthcare spending have also contributed to the growth of the Multiple Sclerosis Drugs market in the country. Additionally, the country's strategic location and favorable business environment have made it an attractive destination for pharmaceutical companies looking to expand their operations in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.